Home » Stocks » MATN

Mateon Therapeutics Inc. (MATN)

Stock Price: $0.1950 USD -0.0050 (-2.50%)
Updated Oct 23, 2020 3:40 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 17.47M
Revenue (ttm) 1.74M
Net Income (ttm) -8.55M
Shares Out 89.60M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.1950
Previous Close $0.2000
Change ($) -0.0050
Change (%) -2.50%
Day's Open 0.2085
Day's Range 0.1880 - 0.2085
Day's Volume 22,690
52-Week Range 0.08 - 0.3

More Stats

Market Cap 17.47M
Enterprise Value 18.29M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 89.60M
Float 57.43M
EPS (basic) -0.10
EPS (diluted) -0.10
FCF / Share -0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 662,753
Short Ratio 8.04
Short % of Float 1.15%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.04
PB Ratio 1.13
Revenue 1.74M
Operating Income -4.81M
Net Income -8.55M
Free Cash Flow -1.13M
Net Cash -819,228
Net Cash / Share -0.01
Gross Margin 100.00%
Operating Margin -276.22%
Profit Margin -491.10%
FCF Margin -64.83%
ROA -18.98%
ROE -79.84%
ROIC 132.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.1950
Target: 0.55
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-------39.1%---
Gross Profit------0.100.16--
Operating Income-4.31-0.71-13.84-13.76-13.68-12.65-8.28-8.07-11.89-18.51
Net Income-6.64-0.71-13.81-13.65-13.65-12.65-8.28-8.08-9.65-23.77
Shares Outstanding59.966.1426.5526.5525.2016.972.801.470.930.33
Earnings Per Share-0.11-0.12-0.52-0.51-0.54-0.75-4.67-5.48-10.37-71.60
Operating Cash Flow-2.28-0.24-10.93-15.24-11.93-12.15-7.00-8.34-11.78-20.43
Capital Expenditures-----0.01-0.02-0.04-0.01--
Free Cash Flow-2.28-0.24-10.93-15.24-11.94-12.17-7.04-8.34-11.78-20.42
Cash & Equivalents0.080.001.1212.0527.2930.037.014.979.994.68
Total Debt0.96---------
Net Cash / Debt-0.880.001.1212.0527.2930.037.014.979.994.68
Book Value16.902.46-0.4812.5025.3529.006.044.558.80-5.26
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mateon Therapeutics Inc.
Country United States
Employees 13
CEO Vuong Trieu

Stock Information

Ticker Symbol MATN
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: MATN
IPO Date August 26, 1993


Mateon Therapeutics, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.